ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
A Site-Aware Representation Learning Framework For Unified Molecular Interaction Modeling and Generative Design.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Unifying drug-target affinity prediction and targeted molecular design within a single interpretable framework remains challenging. Many sequence-based affinity and design methods rely on global target representations without explicitly modeling binding regions, leading to site-level ambiguity in both screening and design. By contrast, structure-based methods require high-quality structural data and are poorly suited to dynamic targets. In this study, a new model named MolDBG is proposed as a unified site-aware framework that combines affinity prediction, binding-site identification, and affinity-conditioned molecular generation within a single architecture. With binding-site supervision, MolDBG prioritizes interaction-critical residues before learning drug-target representations, reducing false positives from misaligned binding sites and improving interpretability. MolDBG achieves competitive performance across all three tasks while enabling site-specific affinity prediction and interpretable binding-site discovery. The framework generalizes to structurally elusive targets, including cryptic pockets and intrinsically disordered proteins. Overall, these results demonstrate that MolDBG is a promising framework for molecular design and screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.